

Daan P Hurkmans

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6582834/publications.pdf>

Version: 2024-02-01

28
papers

621
citations

1039880

9
h-index

887953

17
g-index

28
all docs

28
docs citations

28
times ranked

1028
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 771-777.	2.0	70
2	High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients. <i>European Journal of Cancer</i> , 2021, 144, 41-48.	1.3	64
3	A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. , 2019, 7, 192.		60
4	Correlation between nivolumab exposure and treatment outcomes in non-“small-cell lung cancer. <i>European Journal of Cancer</i> , 2019, 109, 12-20.	1.3	58
5	Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients. <i>Thyroid</i> , 2020, 30, 966-973.	2.4	57
6	CD45RA+CCR7 ^{hi} CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab. , 2019, 7, 149.		44
7	Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer. , 2020, 8, e000586.		39
8	PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma. <i>Oncotarget</i> , 2017, 8, 54722-54734.	0.8	39
9	Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen. <i>Cancers</i> , 2019, 11, 403.	1.7	31
10	Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment. , 2019, 7, 182.		29
11	Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma. , 2020, 8, e001193.		28
12	Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis. <i>ERJ Open Research</i> , 2019, 5, 00179-2019.	1.1	20
13	The prognostic value of weight and body composition changes in patients with non-“small-“cell lung cancer treated with nivolumab. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 657-664.	2.9	18
14	A Serum Protein Classifier Identifying Patients with Advanced Non-“Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2020, 26, 5188-5197.	3.2	15
15	Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors. , 2021, 9, e002344.		12
16	Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 204.	2.4	12
17	Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy. <i>Cancers</i> , 2021, 13, 1370.	1.7	9
18	Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer. , 2020, 8, e001607.		4

#	ARTICLE	IF	CITATIONS
19	Antibiotic use and reduced effectiveness of second-line immunotherapy for lung cancer: all the time or just at the start of treatment?. <i>Annals of Oncology</i> , 2020, 31, 1779-1780.	0.6	3
20	Molecular data show conserved DNA locations distinguishing lung cancer subtypes and regulation of immune genes. <i>Lung Cancer</i> , 2020, 146, 341-349.	0.9	3
21	A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. <i>Annals of Oncology</i> , 2019, 30, v518.	0.6	2
22	Thyroid toxicity and anti-thyroid antibodies as predictive markers for patients treated with anti-PD1 checkpoint therapy. <i>Annals of Oncology</i> , 2019, 30, v527.	0.6	1
23	P2.04-47 Tumor Mutational Load, CD8+ T Cells, Expression of PD-L1 and HLA Class I to Guide Immunotherapy Decisions. <i>Journal of Thoracic Oncology</i> , 2019, 14, S726.	0.5	1
24	Blood-based multiplex kinase activity profiling as a predictive marker for clinical response to checkpoint blockade in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9579-9579.	0.8	1
25	Correlation between nivolumab exposure and treatment outcome in NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9057-9057.	0.8	1
26	P2.04-06 Blood-Based Multiplex Kinase Activity Profiling as a Predictive Marker for Clinical Response to Checkpoint Blockade in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, S709.	0.5	0
27	Identifying t cell profiles that associate with clinical response to anti-PD-1 treatment in non-small cell lung carcinoma (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21239-e21239.	0.8	0
28	Impact of curcumin with and without (+/-) piperine on tamoxifen exposure.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2572-2572.	0.8	0